DAJY(SZ:002030)2023-09-13 17:42Group 1: International Expansion - The company has been actively exploring international markets with a "going out" strategy, focusing on selecting qualified local distributors for collaboration [2] - Employees are regularly sent to participate in international exhibitions to promote the brand and attract potential customers [2] - Sales personnel are divided into different regions with tailored sales targets and plans based on market characteristics and customer needs [2] Group 2: Accounts Receivable Management - The company's accounts receivable have decreased compared to the beginning of the year, and the current accounts receivable situation is considered healthy [2] - Major clients include public hospitals and large independent medical laboratories, with a direct sales model ensuring long-term business relationships [2] Group 3: Future Development Direction - The company has fully entered the IVD field, focusing on clinical diagnostics, public health, and related applications, with plans to strengthen PCR and molecular diagnostics [3] - There is an ongoing effort to diversify business areas and innovate existing products to meet growing customer demands [3] Group 4: Equity Incentive Plans - The company has attempted three equity incentive plans since its listing, with details published on designated information disclosure websites [3] - Despite challenges due to policy and objective conditions, the company remains committed to exploring equity incentives [3] Group 5: Investment Plans - The company continues to implement a "main business development + industry incubation" strategy, focusing on clinical diagnostic technologies and market expansion [3] - Since 2010, the company has successfully promoted industry chain development through investment strategies [3]